PBAC's latest decision on Bimatoprost with timolol maleate: Recommended with restriction (2009). Considered for Reduction of elevated intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension who are not adequately controlled with other treatments.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2009
Submissions
1
2009 → 2009
Eligible population
patients with open-angle glaucoma or ocular hypertension who are not adequately controlled with other treatments
Therapy area
Ophthalmology
Line of therapy
Later-line
Evidence base
RCT, Single-arm, Registry
Primary endpoint
OS | PFS | DFS | ORR | QoL | Surrogate
Key trials
Study 026T, Martinez 2007, Study 021T, Studies 018T, 021T, and 504T
Comparator
bimatoprost 0.03% and timolol maleate 0.5% eye drops given concomitantly
Economic model
Cost-minimisation
Eligible patients/year
10,000
ICER note
Cost-minimisation analysis performed; no ICER calculated